Press release
Investigation announced for Long-Term Investor in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC)
An investigation on behalf of current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares.
Investors who are current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: FENC stocks follows a lawsuit filed against Fennec Pharmaceuticals Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: FENC stocks, concerns whether certain Fennec Pharmaceuticals Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Middle District of North Carolina the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that Fennec Pharmaceuticals Inc. had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, that as a result, the FDA was unlikely to approve the Resubmitted Pedmark NDA, that accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investor in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) here
News-ID: 2637977 • Views: …
More Releases from Shareholders Foundation
Ardent Health, Inc. (NYSE: ARDT) Investor Alert: Deadline in Lawsuit on March 09 …
A deadline is coming up on March 09, 2026 in the lawsuit filed for certain investors of Ardent Health, Inc. (NYSE: ARDT) over alleged securities laws violations by Ardent Health, Inc.
Investors who purchased shares of Ardent Health, Inc. (NYSE: ARDT) have certain options and there are strict and short deadlines running. Deadline: March 09, 2026. Ardent Health, Inc. (NYSE: ARDT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Sina Corporation (formerly NASDAQ: SINA) Investor Alert: Investigation of potent …
An investigation on behalf of investors in shares of Sina Corporation (formerly NASDAQ: SINA) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors inSina Corporation (formerly NASDAQ: SINA shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for investors in Sina Corporation (formerly NASDAQ:…
Lawsuit DEADLINE Alert: Investors who lost money with Stride, Inc. (NYSE: LRN) s …
An investor, who purchased shares of Stride, Inc. (NYSE: LRN), filed a lawsuit over alleged violations of Federal Securities Laws by Stride, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Stride, Inc. (NYSE: LRN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 12, 2026. NYSE: LRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
More Releases for Fennec
Hepatoblastoma Market Growing Rapidly by - Eureka Therapeutics, Fennec Pharmaceu …
DataM Intelligence has published a new research report on "Hepatoblastoma Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/hepatoblastoma-market
The…
Deadline on April 11th coming up in Lawsuit for Investors in Fennec Pharmaceutic …
A deadline is coming up on April 11, 2022 in the lawsuit filed for certain investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC).
Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and there are strict and short deadlines running. Deadline: April 11, 2022. NASDAQ: FENC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S.…
Lawsuit filed for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FE …
An investor, who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), filed a lawsuit over alleged Securities Laws violations by Fennec Pharmaceuticals Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and for certain investors are short and strict deadlines running. Deadline: April 11, 2022. NASDAQ: FENC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Investigation announced for Investors in shares of Fennec Pharmaceuticals Inc. ( …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Fennec Pharmaceuticals Inc.
Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Fennec Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
North Carolina…
Investigation announced for Long-Term Investors in shares of Fennec Pharmaceutic …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Fennec Pharmaceuticals Inc..
Investors who are current long term investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: FENC stocks follows a lawsuit filed against Fennec Pharmaceuticals Inc…
Lawsuit filed for Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FE …
An investor, who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), filed a lawsuit over alleged violations of Federal Securities Laws by Fennec Pharmaceuticals Inc.
Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and for certain investors are short and strict deadlines running. Deadline: November 02, 2020. NASDAQ: FENC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On August 11,…
